share_log

健康元(600380.SH):JKN2403片获得临床试验批准通知书

Joincare Pharmaceutical Group Industry (600380.SH): The JKN2403 tablet has received a clinical trial approval notice.

Gelonghui Finance ·  Dec 19 17:35

On December 19, Glucorate (600380.SH) announced that it has received the "Approval Notice for Drug Clinical Trials" issued by the National Medical Products Administration, approving the clinical trial of its JKN2403 tablets (hereinafter referred to as: JKN2403). JKN2403 is an innovative oral medication independently developed by the company after being introduced from overseas (Phase I clinical trial in Europe has been successful) targeting moderate to severe chronic obstructive pulmonary disease (COPD). It effectively prevents the production of inflammatory mediators associated with COPD by inhibiting the activity of prolyl endopeptidase (PREP), thereby controlling acute exacerbations of COPD. This unique mechanism of action is expected to bring significant benefits to COPD patients and is also anticipated to have a positive impact on the overall progression of the disease. Currently, there are very limited options for oral medications for COPD globally, and the domestic treatment of chronic obstructive pulmonary disease still primarily relies on bronchodilators and Glucocorticoids, lacking varieties of oral anti-inflammatory pharmaceuticals.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment